In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-Type β-lactamases;Sinergismo in vitro tra ulifloxacina e piperacillina/tazobactam verso isolati clinici di Enterobatteri produttori di beta-lattamasi a spettro esteso e AmpC

Infezioni in Medicina

Volumn 18, Issue 4, 2010, Pages 243-247

  Tascini, Carlo ^a   Mantengoli, Elisabetta ^b   Gemignani, Giulia ^a   Leonildi, Alessandro ^a   Di Maggio, Tiziana ^b   Fondelli, Serena ^a   Rossolini, Gian Maria ^b,c   Tagliaferri, Enrico ^a   Menichetti, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

AmpC; ESBL; Piperacillin tazobactam; Synergism; Ulifloxacin

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; ULIFLOXACIN;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG POTENTIATION; ENTEROBACTERIACEAE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG SYNERGISM; ENTEROBACTERIACEAE; FLUOROQUINOLONES; HUMANS; PENICILLANIC ACID; PIPERACILLIN; PIPERAZINES;

EID: 79952224193     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rossolini G.M., Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empiric therapy. Clin. Microbiol. Infect. 14, suppl 6, 2-8, 2008. (Pubitemid 352749376)
2. Winkour P.L., Canton R., Casellas R., Casella J.M., Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamases phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin. Infect. Dis. 32, S94-S103, 2001. (Pubitemid 32424264)
3. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51, 1109-1117, 2003. (Pubitemid 36622067)
4. Rossolini G.M. Acquired metallo-beta-lactamases: an increasing clinical threat. Clin. Infect. Dis. 41, 1557-1558, 2005. (Pubitemid 41691592)
5. Pillay T., Pillay D.G., Adhikari M., Sturm A.W. Piperacillina/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am. J. Perinatol. 15, 47-51, 1998. (Pubitemid 28072978)
6. Pfaller M.A., Segreti J. Overview of the clinical profile and laboratory detection of extended-spectrum beta-lactamases. Clin. Infect. Dis. 42: S153-63, 2006.
7. Roveta S., Schito A.M., Marchese A., Schito G.C. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 26, 366-372, 2005. (Pubitemid 41483466)
8. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial disks tests; Approved Standards, 9th ed. CLSI Document M2- A9, Vol. 26 No 1. Wayne PA: 2006.
9. Jacoby G.A. AmpC beta-lactamases. Clin. Microbiol. Rev. 22, 161-182, 2009.
10. Perilli M., Dell'Amico E., Segatore B., et al. Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J. Clin. Microbiol. 40, 611-614, 2002. (Pubitemid 34130889)
11. Montanari M.P., Mingoia M., Varaldo P.E. In vitro antibacterial activities of AF3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob. Agents Chemother. 45, 3616-3622, 2001. (Pubitemid 33107891)
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility; CLSI document M100-S19, Wayne PA; 2009.
13. Tumbarello M., Sali M., Trecarico E.M., et al. Bloodstream infections caused by extended-spectrum-beta-lactamases-producing E. coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents Chemother. 52, 3244-3252, 2008.
14. DeFife R., Scheetz M.H., Feinglass J.M., Postelnick M.J., Scarsi K.K. Effects on difference in MIC values on clinical outcomes in patients with blood-stream infections caused by gram negative organisms treated with levofloxacin. Antimicrob. Agents Chemother. 53, 174-179, 2009.
15. Drago L., de Vecchi E., Nicola L., Legnani D., Lombardi A., Gismondo M.R. In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or β-lactam against extended-spectrum β-lactamases-producing E. coli. J. Chemother. 17, 46-53, 2005. (Pubitemid 40463756)
16. Lister P.D., Wolter D.J., Wickman P.A., Reisbig M.D. Levofloxacin/ imipenem prevents emergence of high-level resistance among P. aeruginosa strains already lacking susceptibility to one or both drugs. J. Antimicrob. Chemother. 57, 999-1003, 2006.